The American Diabetes Association (ADA)–European Association for the Study of Diabetes (EASD) recommend metformin for all patients with newly diagnosed T2DM [103], whereas the European Society of Cardiology (ESC) guidelines indicate that SGLT-2i or GLP1-RA should be offered first in the presence of high or remarkably high CV risk or of CV disease [104]. Here, GLP1R is linked to type 2 diabetes mellitus.